Newsroom der German Breast Group
In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group.
18.11.2022 Desiree: dose escalation of everolimus published
We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.
10.11.2022 Deutscher Krebskongress
Die GBG ist mit mehreren Postern auf dem 35. Deutschen Krebskongress vom 13. – 16. November 2022 in Berlin vertreten.
08.11.2022 GBG research at SABCS 2022
We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10
14.10.2022 Location of Subcutaneous Trastuzumab Injection
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients´ preference - substudy of the randomised phase III GAIN-2 study
06.10.2022 Einladung zum GBG-IKF Herbst-Symposium
Am 4. November 2022 veranstalten GBG und IKF ihr 1. Herbst-Symposium in Frankfurt/Main.
30.09.2022 Save the date: 20. GBG-Jahrestreffen 2023
Das 20. GBG-Jahrestreffen findet vom 2.-3. März 2023 in Frankfurt statt.
29.09.2022 St.Gallen International Breast Cancer Conference 2023
We are very excited to announce that the next 18th St.Gallen International Breast Cancer Conference 2023 will take place from 15 – 18 March 2023 in Vienna/ Austria.
26.09.2022 Race for Survival 2022
Mit fast 30 TeilnehmerInnen war die GBG beim diesjährigen Race for Survival in Frankfurt.
02.09.2022 August 2022 : Neoadjuvant durvalumab improves survival in early triple-negative breast cancer despite a modest pCR increase – follow-up data from GeparNuevo trial
We are pleased to inform you that long-term outcomes from GeparNuevo trial have been published in Annals of Oncology.
03.08.2022 GBG-Research at EMSO 2022
We are proud to present our research at ESMO Congress 2022 in Paris.
31.07.2022 July 2022: HER2-positive breast cancer patients with brain metastases have the best prognosis compared to other tumor subtypes
We are pleased to inform you that a subanalysis of HER2-positive breast cancer patients with brain metastasis from the BMBC registry has been published in ESMO Open.
14.07.2022 Eight-year data from APHINITY study presented
Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer
30.06.2022 June 2022: Pregnancy does not impact the effectiveness of chemotherapy for breast cancer.
We are pleased to inform you that outcome of pregnant breast cancer patients treated with chemotherapy versus non-pregnant controls has been published in European Journal of Cancer
03.06.2022 WIR ZIEHEN UM!
Bitte beachten Sie unsere neue Anschrift ab dem 18. Juli 2022.
31.05.2022 May 2022: Effect of denosumab added to 2 different nab-paclitaxel regimens as neoadjuvant therapy for primary breast cancer – results from GeparX trial
We are pleased to inform you that primary results from GeparX trial have been published in JAMA Oncology.
24.05.2022 Ovarian Toxicity Assessment
In a paper in "The Breast" we discuss the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials.
23.05.2022 Ergebnisse zur Brustkrebs in der Schwangerschaft
Neue Daten zum Überleben von Brustkrebspatientinnen mit Chemotherapie während der Schwangerschaft
12.05.2022 GBG Research at ASCO 2022
We are happy to present our research at the ASCO Annual meeting June 2022.
30.04.2022 April 2022: Adjuvant pertuzumab significantly improved invasive disease-free survival for HER2-positive, N-positive early breast cancer in the APHINITY trial
We are pleased to inform you that a STEPP analysis of the updated data from the APHINITY trial has been published in European Journal of Cancer
22.04.2022 ESMO Breast Cancer Meeting
GBG research at ESMO Breast Cancer Meeting 2022 May 3rd to 5th in Berlin.
